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EDITORIAL

The relationship of CPE to HIV dementia
Slain by an ugly fact?
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Thomas Henry Huxley, known as “Darwin’s bulldog” for his staunch advocacy of the theory of evolution, is credited with the following statement: “The
great tragedy of science—the slaying of a beautiful
hypothesis by an ugly fact.” The study by Caniglia
et al.1 in this issue of Neurology® demonstrating that
HIV-infected individuals treated with antiretroviral
regimens exhibiting better CNS penetration had
higher rates of HIV dementia is perhaps the “ugly
fact” that might slay a beautiful and widely touted
hypothesis. The finding is not only unexpected, but
counterintuitive.
The authors analyzed a large dataset comprising
nearly 62,000 HIV-infected persons from Europe
and the United States and classified them into 3
groups (high, medium, and low) depending on the
CNS penetration effectiveness (CPE) of their antiretroviral regimen. Hazard ratios for HIV dementia
and several other neurologic complications of AIDS
including toxoplasmosis, cryptococcal meningitis,
and progressive multifocal leukoencephalopathy were
calculated using a pooled logistic regression model for
each of the 3 groups. Not surprisingly, the CPE of the
antiretroviral regimen did not affect the likelihood of
developing AIDS-related CNS opportunistic infections. After all, the predominant driver for the development of these problems is the degree and duration
of cellular immunosuppression, not HIV replication
in the CNS. Unanticipated was the observation of a
direct correlation between high CPE and HIV
dementia. The hazard ratio (95% confidence interval)
for initiating a combined antiretroviral regimen with
a high vs low CPE regimen was 1.74 (1.15, 2.65) for
HIV dementia.
The definition of AIDS dementia used in this
study, “diagnostic procedures that reflect standard
clinical practice in Europe rather than standardized
research criteria,” was necessarily vague as the data
were extracted from clinical records. Because only
235 cases of HIV dementia were identified in more
than 60,000 individuals, it is certain that what is
reported is vastly different than the prevalent HIVassociated neurocognitive disorder (HAND), a

disorder often requiring neuropsychological testing
for detection and estimated to occur in 40%–70%
of HIV-infected individuals.2 Because the pathogenic
mechanisms underlying subtle neurocognitive abnormalities may not be the same as those responsible for
the overt, clinically evident HIV dementia likely represented in this report,3 Caniglia et al. can only provide a partial answer regarding the value and risks of
CPE-guided combined antiretroviral therapy (cART).
HIV infection of the brain has been strongly
implicated as the driver for the development of
HIV dementia, although the pathogenesis of the disorder appears to be multifactorial.4 A high CPE
would be expected to exert maximal benefit on this
disorder, rather than increasing the risk as reported.
Unexpected outcomes may derive from indirect pathways including the elaboration of neurotoxic cytokines, chronic neuroinflammation, perturbations in
cellular channels, oxidative stress, drug toxicity, and
alterations in the blood–brain barrier that might each
contribute to HAND5; however, many of these
mechanisms are the consequence of HIV infection
of the cells within the CNS. The authors suggest
several potential reasons for their observation: (1)
neurotoxicity with deposition of b-amyloid; (2) poor
adherence to the regimen; and (3) the possibility that
these regimens were employed in patients already
demonstrating neurocognitive abnormalities.
CPE was developed to facilitate study of hypothesized variable cART efficacy in the CNS.6 That the
brain can represent a distinct viral reservoir is substantiated by multiple cases of CNS “viral escape,” where
effective control of HIV in the periphery is accompanied by poor viral control in the CNS.7 A variety of
observations including drug characteristics and clinical evidence were used to suggest the relative effectiveness of individual antiretrovirals for CNS
infection, while summing these relative rankings to
classify regimens. Importantly, the CPE ranking does
not incorporate any direct evidence of either CNS
intracellular drug levels or toxicity. To date, this
seemingly rational approach has yielded inconsistent
observations with respect to a correlation of CPE and
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neurologic performance measures and no prospective
study has yet validated it.8–11 Nonetheless, it remains
frequently cited as an approach for selecting effective
therapy. This study emphasizes that such recommendations are premature. Generally, the most tolerable,
potent, and effective cART should be selected,
regardless of CPE. In rare instances of viral escape
in CSF, selection of cART based on viral resistance
of the CSF isolate is necessary.
A dogmatic approach in selecting cART to prevent
or treat HAND at the current time seems unwarranted. Further development of ranking schemes for
effectiveness in brain may be useful, perhaps including considerations for alternative mechanisms competing with cART efficacy against the virus. The
brain is a large potential reservoir for HIV infection
and may be responsible for the generation of mutations and resistant HIV strains that reseed the body.
Effective treatment of HIV must include controlling
HAND and clearing the virus from the brain. More
detailed prospective studies, encompassing broader
possible mechanisms of action, will be needed to
clearly define the risk and benefit of our therapeutic
regimens. Meanwhile, it remains remarkable that
most cART regimens successfully control the virus
when taken faithfully. It would be inappropriate for
fear of toxicity to become an excuse for noncompliance with the successful HIV therapies available.
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